. (2013). Interactive effects of 1, 25-dihydroxyvitamin D3 and soy protein extract (SPE) on oral cancer growth in vitro: evidence for potential functional relationships. Functional Foods in Health and Disease, 3(6), 183-202. http://digitalscholarship.unlv.edu/dental_fac_articles/53 Few studies have evaluated whole soy extract, containing a combination of these isoflavones and other bioreactive compounds, which may function synergistically and more effectively against oral cancers. Preliminary work by this group has now demonstrated whole soy protein extract (SPE) inhibits oral cancer cell growth specifically and selectively, through independent cellcycle and apoptotic pathways. However, more recent evidence now suggests that ingestion of vitamin D 3 , either in dietary foods or supplements may potentiate the activity of soy components and their anti-tumor effects.
glucosinolates, indoles, isothiocyanates, protease inhibitors, plant sterols, allium compounds, limonenes, selenium, vitamin C, vitamin E, and dietary fiber all have noted inhibitory effects on oral cancer [10] [11] [12] . The majority of studies focusing on dietary prevention and therapy for oral cancer have explored the role of flavonoids, part of a large family of polyphenolic compounds made by plants [13] [14] [15] [16] [17] [18] [19] . New evidence, however, has suggested that another subclass of flavonoids highly concentrated in soybeans and soy-containing foods (isoflavones) may also exhibit potent effects specific for oral cancers [20] [21] [22] [23] [24] .
Soy isoflavones: Many of these studies have focused on specific isoflavones derived from soy, which include Daidzein, Genistein, and Glycitein, which are capable of inhibiting growth and proliferation of oral cancers [25] [26] [27] . Although significant, these effects were observed in vitro at supraphysiologic levels (> 10 mol/L), which may be neither safe (in vivo) nor feasible through dietary consumption or nutritional supplementation. This group was among the first to demonstrate that soy proteins, in combination, may be useful and effective against oral cancers at concentrations that approximate physiologic serum levels (0-2 mol/L) achievable through dietary or supplement intake, which may help to explain why diets rich in fruits, vegetables, and soy protein are associated with protection against development and progression of oral cancers [24] . There is some evidence suggesting that synergistic effects of multiple isoflavones in whole soy foods and soy extracts may be responsible for preventing the negative side effects observed with single agent administration to normal cells, as well as the expression of anti-cancer effects at much lower serum concentrations [28, 29] .
Soy interactions with Vitamin D3:
Researchers have focused on the direct, antitumor properties of soy isoflavones on oral cancers; however, few studies have evaluated the interactive effect of whole soy (or soy-derived isoflavones) via regulation of P450 enzymes, involved in the metabolism of Vitamin D. However, there is evidence to suggest this may be a significant regulatory pathway of anti-cancer action as the few studies completed to date have demonstrated that soy protein (both in vivo and in vitro) directly influences the expression of P450 enzymes in other cancers -thereby regulating cellular Vitamin D metabolism [30] [31] [32] . For example, CYP24 is often highly expressed in many cancers, which degrades newly synthesized or serum-derived levels of 1, 25-dihydroxyvitamin D3 [33] [34] [35] [36] . These studies suggest that dietary intake of soy may result in a consistent down-regulation of CYP24, thereby enabling the functions and anticancer properties of Vitamin D [32, 37] .
Vitamin D and oral cancer: Consistent with these laboratory findings, large-scale population studies clearly demonstrated that low serum vitamin D levels and vitamin D deficiencies are associated with much higher cancer risk [38, 39] . More specifically, epidemiologic and casecontrolled studies have confirmed that low vitamin D levels and deficiency are strongly associated with OPC risk [40, 41] . The primary mechanism of Vitamin D action is mediated through binding of either 1, 25(OH) 2 D (active form) or 25(OH)D (less active form) to the vitamin D receptor (VDR), which is a member of the nuclear receptor super family of steroid and thyroid hormones with gene regulatory and consequent anti-proliferative properties [42, 43] . Vitamin D mechanism: Binding of 1, 25(OH) 2 D to the VDR (either in the cell nucleus or cytoplasm) promotes association of the VDR-1,25(OH) 2 D complex with the retinoid X receptor (RXR) [41, 42] . The 1, 25(OH)2D-VDR-RXR complex binds to vitamin D-response elements in DNA which operate to initiate gene transcription. Activation of the VDR by 1, 25(OH) 2 D can restore or enhance pro-apoptotic effects in different cancer cells through transcriptional activation of bax and p-calpain, two effective pro-apoptotic proteins [44, 45] . Although much is known about these effects in other cancers, few studies to date have evaluated Vitamin D in oral cancers [46, 47] .
Evidence for interactive effects:
There is now evidence that many oral cancers may, in fact, exert their effects on cellular Vitamin D metabolism by changing the availability of (or affecting the ability to bind to) the VDR. New evidence demonstrates that some oral cancers may exhibit reduced VDR expression [48, 49] . In addition, Ras activation (common in many oral cancers) might also impair Vitamin D-mediated transcription. Cytochrome p450 (CYP24, the enzyme responsible for degrading vitamin D) exhibited the highest up-regulation (196-fold increase) from a screening of more than 4,500 genes in one oral cancer cell line [47] . This may provide some evidence consistent with the observation that CYP24 mutations may lower oral cancer risk compared with wild type, after adjusting for age, gender, alcohol consumption, and smoking status [50] .
Based upon this information, the overall objective of this study is to evaluate the anticancer properties of soy protein extract (SPE), which is available as a dietary supplement and most closely resembles the whole soy food that most US adults are likely to consume. The effects of SPE against well-characterized oral cancer cell lines will be evaluated using in vitro analysis methods. These experiments will be performed in conjunction with administration of Vitamin D to determine the interactive effects of SPE on Vitamin D-induced oral cancer growth inhibition.
Based upon previous work that determined SPE and Vitamin D are each, independently sufficient to mediate the proliferative phenotypes of these cancers in this experimental model, the working hypothesis is that co-administration will synergistically amplify these effects. Using in vitro analysis methods, any quantitative differences in viability and growth of oral cancer cells will be measured. The specific aims will be to characterize the inhibition of oral cancer proliferation induced by SPE administration in combination with Vitamin D, as well as any effects on cellular viability. The activation and expression of the apoptotic regulators, caspase-2, caspase-8, and bax, will also be assessed.
MATERIALS AND METHODS:
Cell culture and cell lines: The human oral squamous cell carcinoma cell lines, CAL 27 (CRL-2095) and SCC25 (CRL-1628), were obtained from American Type Culture Collection (ATCC: Manassas, VA). CAL 27 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) with 4.0 mM L-Glutamine adjusted to contain 3.7 g/L sodium bicarbonate, 4.5 g/L glucose, and 110 mg/L sodium pyruvate, obtained from HyClone (Logan, UT). SCC25 cells were maintained in a 1:1 mixture of DMEM and Ham's F12 medium with 2.5 mM L-Glutamine, modified to contain 15 mM 4-2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES), 0.5 mM sodium pyruvate, and 1.2 g/L sodium bicarbonate.
The normal oral gingival fibroblast cell line, HGF-1 (CRL-2014), was also obtained from American Type Culture Collection (ATCC: Manassas, VA). HGF-1 cells were maintained in DMEM with 4 mM L-Glutamine, adjusted to contain 3.7 g/L sodium bicarbonate and 4.5 g/L glucose, from HyClone (Logan, UT). All cell culture media was supplemented with 1% Penicillin (10,000 units/mL)-Streptomycin (10,000 g/mL) solution and 10% fetal bovine serum (FBS) obtained from HyClone (Logan, UT). Cells were cultured in 75 cm 2 BD Falcon tissueculture treated flasks (Bedford, MA) at 37°C and 5% CO 2 in humidified chambers.
Materials: 1, 25-dihydroxyvitamin D 3 (VitD 3 ) was obtained from GNC Preventive Nutrition® (Pittsburgh, PA). Proliferation and viability assays were performed in the appropriate complete media, with and without the addition of VitD 3 (10, 50 and 125 nmol) . This concentration range (25 -312.5 ng/mL) approximates the physiologic concentrations of the less active form of VitD 3 , but supraphysiologic concentrations of the active form, which allowed for short-term in vitro effects to be observed [42, 51] . This also enabled comparison with the only other studies examining OPC cell lines [46, 47] , which utilized similar concentration ranges (1, 10, 100 nmol or 2.5, 125, 250 ng/mL). Soy protein extract (SPE) was obtained from GNC Preventive Nutrition® (Pittsburgh, PA). Equivalent amounts of SPE were used to approximate the low-(10 g/mL), mid-(50 g/mL), and high-range (100 g/mL) concentrations of flavonoid extracts utilized in prior in vitro studies [16, 17, 19] , which were 10, 50, and 100 g/mL. In addition to total SPE, the concentration of soy isoflavones for each experimental condition was also calculated to determine if these concentrations were within the normal physiologic range (0 -10 /L).
Quantitative analysis provided by GNC demonstrated each gram of SPE contained 0.86 -2.6 mg of isoflavones, with 0.30-0.91mg/g Daidzein (all forms), 0.52-1.56 mg/g Genistein (all forms), and 0.04-0.13mg/g Glycitein (all forms), resulting in an approximate ratio of 7:12:1 (Daidzein, Genistein, Glycitein, respectively). The proportional molecular weights (MW) of the soy isoflavones in the SPE were calculated to be: To derive physiologic concentration, the total amount of SPE used (mg/L) is multiplied by the percentage of isoflavones contained within this amount; the proportional amount of total isoflavone is then divided by the averaged MW to yield moles (M/L); this amount is converted to derive final isoflavone concentration (mol/L) as follows:
10 g/mL SPE = 10 mg/L or 0.01 g SPE 0.01 g SPE (0.0026 isoflavone concentration per g/SPE) = 0.000026 g total isoflavone 0.000026 g / 265.31 MW = 0.00000000979 mol/L (1,000,000
Previous studies have demonstrated normal physiological levels of total plasma soy isoflavones vary between 1 and 2 mol/L [52, 53] , although higher concentrations have been observed among Asian populations [54, 55] . Based upon this information, the range of soy isoflavone concentrations utilized in this study (0.1 -1.0 mol/L) was within the normal physiologic range. The individual concentrations for the active soy isoflavones are as follows:
Proliferation: Proliferation assays were performed in the appropriate complete media, with and without the addition of SPE, VitD 3 or both, prior to the start of each experimental assay. In brief, cells were plated in Corning Costar high-throughput, 96-well assay plates (Corning, NY) at a concentration of 1.2 x 10 4 cells per well, which roughly approximates 30-40% confluence per well at the onset of each assay. Proliferation was subsequently measured after three days. Cultured cells were fixed after 72 hours or day 3 using 50 L of 10% buffered formalin, and were stained with crystal violet 1% aqueous solution (Fisher Scientific: Fair Lawn, NJ). The relative absorbance was measured at 630 nm using a Bio-Tek ELx808 microplate reader (Winooski, VT). Data was analyzed and graphed using Microsoft Excel (Redmond, WA) and SPSS (Chicago, IL). Three separate, independent replications of each experiment were performed.
Statistics:
Comparisons of the effects of treatments were made using two-tailed t-tests with α = .05. All samples were analyzed using two-tailed t-tests as departure from normality can make more of a difference in a one-tailed than in a two-tailed t test [56] . As long as the sample size is moderate (> 20) for each group, quite severe departures from normality make little practical difference in the conclusions reached from these analyses. Multiple analyses involving twosample t-tests have higher probability of Type I errors, leading to false rejection of the null hypothesis (H 0 ). To confirm the effects of these experiments, one-way analysis of variance (ANOVA) was used to assess statistical significance, p <0.05. In addition, the data were analyzed after each experimental set to determine whether if the growth inhibition was normally distributed. This analysis revealed the cumulative probably of these data falling within a normal distribution was 0.99379 or 99.38% (= 0.0125). Because the outcome measures were tested against a three (individual tests of SPE or VitD 3 concentration) or four (combination of SPE and VitD 3 concentrations) predictors, a Bonferroni-adjusted significance level of  = 0.0125 was used to account for the increased possibility of type I error ( = 0.05 / 4 = 0.0125).
Survival and viability:
Prior to plating cells for proliferation assays, aliquots of trypsinized cells were stained using Trypan Blue (Sigma: St. Louis, MO), and live cells were enumerated by counting the number of Trypan-blue negative cells using a VWR Scientific Counting Chamber (Plainfield, NJ) and a Zeiss Axiovert 40 inverted microscope (Gottingen, Germany). At each time point (d1-d3), several wells were processed using the Trypan stain, and live cells were enumerated using this procedure. RNA standard: GAPDH was obtained from control cells, human gingival fibroblasts (HGF-1) 0.3-0.5 x 10 6 cells/mL were used to establish the minimum threshold (CT) and saturation (CS)
RT-PCR:
cycles required for calibration and concentration comparisons using relative endpoint (RE) RT-PCR. GAPDH signal detection above background or threshold (CT) required a minimum of ten cycles (C10), with saturation (CS) observed at C40. Based upon this data, RE-PCR was performed at C35, above the lower detection limit but below the saturation limit.
In brief, one (1) g of template (total) RNA was used for each reaction. The reverse transcription step ran for 30 minutes at 47°C, followed by denaturation for 2 minutes at 94°C. Thirty-five amplification cycles were ran, consisting of 20 second denaturation at 94°C, 30 seconds of annealing at 58°C, and 6.5 minutes of extension at 72°C. Final extension was run for 5 minutes at 72°C. Reaction products were separated by gel electrophoresis using Reliant 4% NuSieve® 3:1 Plus Agarose gels (Lonza: Rockland, ME). Bands were visualized by UV illumination of ethidium-bromide (EtBr)-stained gels and captured using a Kodak Gel Logic 100 Imaging System and 1D Image Analysis Software (Eastman Kodak: Rochester, NY). Quantification of RT-PCR band densitometry was performed using Adobe (San Jose, CA) Photoshop imaging software, Image Analysis tools.
RESULTS:
A dose-dependent response relationship between growth inhibition and VitD 3 administration was observed in all three oral squamous cell carcinoma cell lines (CAL27, SCC25, SCC15) with increasing concentrations resulting in more robust inhibition of cellular proliferation (Figure 1 ). For example, the lowest concentration VitD 3 (10 nmol or 2.5 ng/mL) reduced growth significantly (compared with baseline controls) by 11%, 6.5%, and 12% in CAL27, SCC25, and SCC15 cells (p<0.05), respectively. Higher concentrations of VitD 3 (50 nmol or 125 ng/mL) induced greater growth inhibition, reducing proliferation by 18.6%, 38.8%, and 18.2%, respectively (p<0.01). The highest concentration (125 nmol or 312.5 ng/mL) induced the greatest effects, inhibiting proliferation by 29.1%, 43.1%, and 32.1%, respectively -which was determined to be the observed growth inhibitory maximum (GI MAX ) concentration. Higher concentrations induced ever-diminishing effects above this concentration 150 -300 nmol or 375 -750 ng/mL (data not shown), which approximate physiologic levels of vitamin D intoxication [51] .
Growth inhibition was also observed following SPE administration among all three cell lines, although these effects were not uniform. More specifically, the lowest concentration of SPE (10 g/mL or 2 M/L) was sufficient to inhibit growth significantly by 25.8%, 20.2%, and 15.2% in CAL27, SCC25, SCC15 cells, respectively (p<0.05). The growth inhibitory maximum (GI MAX ) concentration of SPE was observed at 50 g/mL (10 M/L), which inhibited growth by 39.1%, 29.2%, and 19.2% in CAL27, SCC25, SCC15 cells, respectively (p<0.01). However, the highest concentration evaluated (100 g/mL or 20 M/L) was not sufficient to inhibit CAL27 growth as intensely (-31.3%, p<0.01) and the effects on SCC25 and SCC15 were indistinguishable from those observed at 50 g/mL (p>0.05). No greater effects were observed above this concentration range.
To assess any additive, interactive or synergistic effects, three-day growth assays were performed using of concomitant administration of VitD 3 (HGF-1) , which exhibited no growth inhibition, but rather stimulation of cell proliferation, which ranged between 18.2% and 41.2%.
To determine if the growth inhibitory effects of VitD 3 or SPE administration on these cell lines was due, at least in part, to alterations in cell survival or viability -each cell line and experimental treatment was analyzed at each time point of the proliferation assays and the viability assessed (Table 1 ). This analysis revealed that VitD 3 and SPE administration was sufficient to decrease viability among the oral cancer cell lines. More specifically, the baseline viability of CAL27 cells (94.4%) was lowered by VitD 3 The GI MAX concentration of VitD 3 [H] was then combined with the low-dose of SPE [L], which resulted in a significant change in growth inhibition in all three cell lines. CAL27 growth, for example, was inhibited by 45.1%, which was greater than the inhibition observed under either previous combination (-41.8% and -41.5%) or either alone (-29.1%, -39.1%). Similar results were observed for SCC15 (-47.3%) and SCC25 (-53.2%), which was also greater than either previous combination examined (SCC15: -31.2%, -33.2%; SCC25: -37.1%, -32.1%) or VitD 3 The combined administration of VitD 3 and SPE had more variable effects. To illustrate, the viability of CAL27, SCC25 and SCC15 was reduced under VitD 3 To determine if the growth inhibitory and viability reducing effects of VitD3 and SPE administration were associated with differential gene expression, relative endpoint (RE) RT-PCR was performed on total RNA isolated from each cell line following combination therapy using oligonucleotide primers specific to the mRNA of critical apoptosis regulatory genes caspase-2 (an apoptosis initiator), caspase-8 (an apoptosis effector), and bax, as well as the cell-cycle regulatory genes c-myc, ornithine decarboxylase (ODC) and the tumor suppressor, p53 ( Figure  3 ). Three VitD 3 -SPE combinations were evaluated due to their differential effects on growth, as well as viability. These experimental conditions included VitD 3 
DISCUSSION:
The overall objective of this study was to evaluate the anti-cancer properties of soy protein extract (SPE), which is available as a dietary supplement and most closely resembles the whole soy food that most US adults are likely to consume as edamame, tofu, or other soy-based products. The effects of SPE against well-characterized oral cancer cell lines were evaluated using in vitro analysis methods in conjunction with administration of Vitamin D to determine the interactive effects of SPE on Vitamin D-induced oral cancer growth inhibition. Based upon previous work that determined SPE and Vitamin D are each, independently sufficient to mediate the proliferative phenotypes of these cancers in this experimental model, the working hypothesis was that co-administration would synergistically amplify these effects. These results of this study clearly demonstrated these anti-tumor effects, which are consistent with previous reports and observations. However, this may be the first study to evaluate the co-administration of SPE and Vitamin D, as well as the first to report synergistic effects on growth inhibition of oral cancer cell lines (under conditions of Vitamin D GI MAX concentrations).
Although this type of research has been extremely useful for identifying agents that are now clinically demonstrated as effective agents against specific cancers, a number of limitations must be considered when evaluating the outcomes of this study. First, one limitation of this and other preclinical studies involves the use of oral cancer cell lines, as there may be underlying dissimilar genetic mutations that might potentially influence the experimental outcomes. For example, the SCC25 cell line has been found to contain a deletion in the cdk1 promoter that contains a key transcriptional repressor region [60] . In addition, the CAL27 cell line contains a nonsense mutation in the SMAD4 gene, while SCC15 cells were found to harbor a missense mutation in SMAD2 -both signal TGF-β transduction proteins [61] . Finally, both CAL27 and SCC15 cells contain a single nucleotide polymorphism in the S100A2 gene, a calcium-binding tumor suppressor protein, although this does not appear to alter their propensity for growth, migration or invasion [62] . However, a growing body of evidence demonstrates that deregulation and reduced expression of key tumor suppressors, such as p16, in these cell lines may, in fact, be the result of hyper methylation -providing further justification to elucidate the interconnected roles of dietary components and transcriptional regulation in the growth and progression of oral cancers [63] [64] [65] .
Another limitation to be considered is that SPE, unlike Vitamin D, contains multiple bioactive substances in addition to the soy isoflavones (Daidzein, Genistein, Glycitein), which may have direct effects on cellular behaviors despite their relatively low concentrations [66, 67] . These SPE components include, but are not limited to, phytates (inositol hexaphosphate), oligosaccharides, saponins, Kunitz inhibitor and Bowman-Birk Inhibitor (BBI) [68] . Some previous studies have demonstrated that saponins were capable of exerting growth inhibiting effects on colon cancer cell lines in vitro [62, 69, 70] . In addition, other studies have demonstrated cytotoxicity and apoptotic effects on oral cancers in vitro using saponins [71] [72] [73] . However, these effects in animal and human models may be severely limited due to low absorption rates, as well as extremely low serum concentrations that are far lower than the experimental concentrations that were evaluated [66, 67] .
Finally, some recent studies have demonstrated there may be possible adverse effects of elevated 25(OH)D concentrations on cancer risk in prostate, breast, pancreas, and esophageal cancers, suggesting that these effects may depend on dose, timing and duration of exposure, as well as tissue specific, lifestyle, and genetic factors [74, 75] . Although J-or U-shaped risk curves have been proposed to describe the noted associations in these studies, confounding factors present in the original studies are likely responsible for these findings [51, 74] . For example, outcomes of intervention trials of supplemental Vitamin D were inconclusive due to the lack of baseline vitamin D status reports of trial participants and consequent dose adequacy estimates [51, 74, 75] . This may suggest that studies focused on the dose administered, rather than their effect on alleviating deficiency, achieving adequacy, or adding to pre-trial adequate serum levels, might have significantly affected the dose-response curves and further complicated the interpretation of trial outcomes.
CONCLUSION:
Although many clinical studies have suggested Vitamin D status, intake, and supplementation may have significant effects on oral cancer risk, progression, and mortality, growing epidemiologic evidence now suggests that dietary patterns, which may include the intake of other cancer preventing foods (such as soy) may influence these effects [1, 6] . This study is among the first to examine the relationships between Vitamin D and soy administration in oral cancer cells, which provides specific information about the mechanisms and pathways that may be modulated along with growth inhibition and reduced viability. This study provides the first direct evidence of the magnitude of these relationships, which may be particularly useful to oncologists, oral health researchers, and nutrition epidemiologists as they analyze and develop rubrics for generalizing the health protective effects of diet and dietary supplements, as well as the most effective ancillary treatment options for patients with oral cancer. 
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